CN114929205B - 包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法 - Google Patents
包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法 Download PDFInfo
- Publication number
- CN114929205B CN114929205B CN202080076963.3A CN202080076963A CN114929205B CN 114929205 B CN114929205 B CN 114929205B CN 202080076963 A CN202080076963 A CN 202080076963A CN 114929205 B CN114929205 B CN 114929205B
- Authority
- CN
- China
- Prior art keywords
- lipid
- cedna
- itr
- pharmaceutical composition
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962896980P | 2019-09-06 | 2019-09-06 | |
| US62/896,980 | 2019-09-06 | ||
| US201962910720P | 2019-10-04 | 2019-10-04 | |
| US62/910,720 | 2019-10-04 | ||
| US201962940104P | 2019-11-25 | 2019-11-25 | |
| US62/940,104 | 2019-11-25 | ||
| PCT/US2020/049266 WO2021046265A1 (en) | 2019-09-06 | 2020-09-03 | Lipid nanoparticle compositions comprising closed-ended dna and cleavable lipids and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114929205A CN114929205A (zh) | 2022-08-19 |
| CN114929205B true CN114929205B (zh) | 2024-09-03 |
Family
ID=74853052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080076963.3A Active CN114929205B (zh) | 2019-09-06 | 2020-09-03 | 包括末端封闭式dna和可切割脂质的脂质纳米颗粒组合物及其使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220280427A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4025196A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7700101B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114929205B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020342668B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3150452A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL291038A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021046265A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021060440A1 (ja) * | 2019-09-26 | 2021-04-01 | 日油株式会社 | 脂質ナノ粒子の凍結乾燥組成物 |
| US12534435B2 (en) | 2020-03-27 | 2026-01-27 | Generation Bio Co. | Lipids and nanoparticle compositions thereof |
| CN115968280A (zh) * | 2020-05-18 | 2023-04-14 | 世代生物公司 | 新型脂质及其纳米颗粒组合物 |
| AU2021307952A1 (en) * | 2020-07-17 | 2023-03-02 | Generation Bio Co. | Methods for encapsulating polynucleotides into reduced sizes of Lipid nanoparticles and novel formulation thereof |
| MX2023001109A (es) | 2020-07-27 | 2023-04-24 | Anjarium Biosciences Ag | Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas. |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CN117098541A (zh) | 2020-11-25 | 2023-11-21 | 阿卡格拉医药公司 | 用于递送核酸的脂质纳米粒及相关使用方法 |
| WO2022261101A1 (en) * | 2021-06-07 | 2022-12-15 | Generation Bio Co. | Apoe and apob modified lipid nanoparticle compositions and uses thereof |
| CN117642380A (zh) * | 2021-06-14 | 2024-03-01 | 世代生物公司 | 阳离子脂质及其组合物 |
| WO2022271780A1 (en) * | 2021-06-22 | 2022-12-29 | Intellia Therapeutics, Inc. | Methods for in vivo editing of a liver gene |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| US12251471B2 (en) * | 2021-07-26 | 2025-03-18 | Oregon State University | Inhalable therapeutics |
| CN118251212A (zh) * | 2021-09-30 | 2024-06-25 | 日油株式会社 | 用于将核酸递送至淋巴管内皮细胞的脂质纳米颗粒 |
| CN114432502B (zh) * | 2021-12-31 | 2023-02-03 | 中山大学附属第八医院(深圳福田) | 一种负载op3-4多肽、抗cxcl9抗体的水凝胶及其制备方法与应用 |
| WO2023190175A1 (ja) * | 2022-03-28 | 2023-10-05 | 日油株式会社 | 末梢血単核細胞へ核酸を送達するための脂質ナノ粒子およびこれを用いて末梢血単核細胞へ核酸を送達する方法 |
| JPWO2023190176A1 (cg-RX-API-DMAC7.html) * | 2022-03-28 | 2023-10-05 | ||
| WO2023230587A2 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| WO2024112943A1 (en) * | 2022-11-22 | 2024-05-30 | University Of Maryland, Baltimore | Activated nanotherapy for sickle cell disease |
| WO2024140893A1 (zh) | 2022-12-29 | 2024-07-04 | 辽宁键凯科技有限公司 | 一种类固醇-阳离子脂质化合物及其应用 |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025188836A1 (en) * | 2024-03-05 | 2025-09-12 | Saliogen Therapeutics, Inc. | Compositions and methods of using gene coding for treating ocular disease |
| WO2025213135A1 (en) * | 2024-04-04 | 2025-10-09 | The Brigham And Women's Hospital, Inc. | Lipid nanoparticles for the treatment of vascular diseases |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019051289A1 (en) * | 2017-09-08 | 2019-03-14 | Generation Bio Co. | FORMULATIONS OF LIPID NANOPARTICLES OF NON-VIRAL CAPSID-FREE DNA VECTORS |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| CA2289702C (en) | 1997-05-14 | 2008-02-19 | Inex Pharmaceuticals Corp. | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| AU6814901A (en) | 2000-06-01 | 2001-12-11 | Univ North Carolina | Methods and compounds for controlled release of recombinant parvovirus vectors |
| WO2002087541A1 (en) | 2001-04-30 | 2002-11-07 | Protiva Biotherapeutics Inc. | Lipid-based formulations for gene transfer |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| EP1604022A2 (en) | 2003-03-06 | 2005-12-14 | Oligo Engine, Inc. | Modulation of gene expression using dna-rna hybrids |
| US20050148531A1 (en) | 2003-05-15 | 2005-07-07 | Todd Hauser | Modulation of gene expression using DNA-DNA hybrids |
| CN1882693B (zh) | 2003-09-15 | 2012-08-15 | 普洛体维生物治疗公司 | 聚乙二醇修饰的脂质化合物及其应用 |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| JP5639338B2 (ja) | 2005-07-27 | 2014-12-10 | プロチバ バイオセラピューティクス インコーポレイティッド | リポソームの製造システムおよび製造方法 |
| CA3144493A1 (en) | 2006-10-03 | 2008-04-10 | Arbutus Biopharma Corporation | Lipid containing formulations |
| WO2008103276A2 (en) | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
| EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
| EP2279254B1 (en) | 2008-04-15 | 2017-07-05 | Protiva Biotherapeutics Inc. | Novel lipid formulations for nucleic acid delivery |
| EP2310440A4 (en) | 2008-07-10 | 2013-06-05 | Serina Therapeutics Inc | POLYOXAZOLINES WITH INTERNAL END GROUPS, POLYOXAZOLINES MANUFACTURED FROM PROTECTED INITIAL GROUPS AND CORRESPONDING COMPOUNDS |
| KR20220038506A (ko) | 2009-06-10 | 2022-03-28 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| EP3391877A1 (en) | 2010-04-08 | 2018-10-24 | The Trustees of Princeton University | Preparation of lipid nanoparticles |
| WO2011139911A2 (en) | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| US20120225129A1 (en) | 2010-08-20 | 2012-09-06 | Cerulean Pharma Inc. | Conjugates, particles, compositions, and related methods |
| ES2987915T3 (es) | 2010-09-20 | 2024-11-18 | Sirna Therapeutics Inc | Nuevos lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos |
| EP2500434A1 (en) * | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| EP4074693A1 (en) * | 2011-06-08 | 2022-10-19 | Translate Bio, Inc. | Cleavable lipids |
| CA2853689C (en) | 2011-11-04 | 2020-06-30 | Nitto Denko Corporation | Method of producing lipid nanoparticles for drug delivery |
| WO2013073480A1 (ja) * | 2011-11-18 | 2013-05-23 | 日油株式会社 | 細胞内動態を改善したカチオン性脂質 |
| HK1206644A1 (en) * | 2012-03-29 | 2016-01-15 | Shire Human Genetic Therapies, Inc. | Lipid-derived neutral nanoparticles |
| CN110003066B (zh) | 2013-11-18 | 2021-09-03 | 阿克丘勒斯治疗公司 | 用于rna递送的可电离的阳离子脂质 |
| US10426737B2 (en) | 2013-12-19 | 2019-10-01 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| CA2953341C (en) | 2014-06-25 | 2023-01-24 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| WO2016079197A1 (en) * | 2014-11-18 | 2016-05-26 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Delivery enhancers for conjugated sirna and lipid nanoparticles |
| JP6640750B2 (ja) * | 2015-01-30 | 2020-02-05 | 日油株式会社 | カチオン性脂質 |
| HUE067372T2 (hu) | 2015-06-29 | 2024-10-28 | Acuitas Therapeutics Inc | Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására |
| CN108368028B (zh) | 2015-10-28 | 2021-09-03 | 爱康泰生治疗公司 | 用于递送核酸的新型脂质和脂质纳米颗粒制剂 |
| DK3386484T3 (da) | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
| US12678515B2 (en) | 2015-12-30 | 2026-07-14 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| EP3315125A1 (en) * | 2016-10-31 | 2018-05-02 | Silence Therapeutics (London) Ltd | Lipid nanoparticle formulation |
| WO2018237369A2 (en) * | 2017-06-23 | 2018-12-27 | Vical Incorporated | Lipid nanoparticle (lnp)-mediated delivery of a crispr-expressing plasmid dna for treating chronic hepatitis b virus infection |
| CA3075168A1 (en) * | 2017-09-08 | 2019-03-14 | Generation Bio Co. | Modified closed-ended dna (cedna) |
| AU2019221642A1 (en) * | 2018-02-14 | 2020-07-09 | Generation Bio Co. | Non-viral DNA vectors and uses thereof for antibody and fusion protein production |
| CA3094057C (en) * | 2018-03-27 | 2025-04-08 | Nof Corporation | CATIONIC LIPID WITH IMPROVED INTRACELLULAR DYNAMICS |
-
2020
- 2020-09-03 CN CN202080076963.3A patent/CN114929205B/zh active Active
- 2020-09-03 WO PCT/US2020/049266 patent/WO2021046265A1/en not_active Ceased
- 2020-09-03 US US17/632,262 patent/US20220280427A1/en not_active Abandoned
- 2020-09-03 CA CA3150452A patent/CA3150452A1/en active Pending
- 2020-09-03 AU AU2020342668A patent/AU2020342668B2/en active Active
- 2020-09-03 EP EP20860233.4A patent/EP4025196A4/en active Pending
- 2020-09-03 JP JP2022514708A patent/JP7700101B2/ja active Active
-
2022
- 2022-03-01 IL IL291038A patent/IL291038A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019051289A1 (en) * | 2017-09-08 | 2019-03-14 | Generation Bio Co. | FORMULATIONS OF LIPID NANOPARTICLES OF NON-VIRAL CAPSID-FREE DNA VECTORS |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4025196A1 (en) | 2022-07-13 |
| IL291038A (en) | 2022-05-01 |
| AU2020342668B2 (en) | 2025-10-09 |
| US20220280427A1 (en) | 2022-09-08 |
| JP7700101B2 (ja) | 2025-06-30 |
| CN114929205A (zh) | 2022-08-19 |
| AU2020342668A1 (en) | 2022-03-03 |
| EP4025196A4 (en) | 2023-07-12 |
| WO2021046265A1 (en) | 2021-03-11 |
| JP2022546597A (ja) | 2022-11-04 |
| CA3150452A1 (en) | 2021-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7700101B2 (ja) | 閉端dnaおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法 | |
| CN114787127B (zh) | 可电离脂质及其纳米颗粒组合物 | |
| US20220119840A1 (en) | Closed-ended dna (cedna) and use in methods of reducing gene or nucleic acid therapy related immune response | |
| JP7590963B2 (ja) | 対称的な修飾型逆位末端反復配列を含む修飾型閉端dna(cedna) | |
| US20220175968A1 (en) | Non-active lipid nanoparticles with non-viral, capsid free dna | |
| BR112020013319A2 (pt) | vetores de dna de extremidade fechada obteníveis a partir de síntese livre de células e processo para obter vetores de cedna | |
| CN117897143A (zh) | Apoe和apob修饰的脂质纳米颗粒组合物及其用途 | |
| US12415002B2 (en) | Non-viral DNA vectors and uses thereof for expressing phenylalanine hydroxylase (PAH) therapeutics | |
| CN115968280A (zh) | 新型脂质及其纳米颗粒组合物 | |
| US20220184231A1 (en) | Closed-ended dna (cedna) and immune modulating compounds | |
| CA3172591A1 (en) | Non-viral dna vectors and uses thereof for expressing gaucher therapeutics | |
| WO2024249298A2 (en) | Modified closed-ended dna (cedna) vectors, compositions, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |